CAJ | 학술논문

目的研究重组人白细胞介素-2(rIL-2)联合化疗治疗多发性骨髓瘤(MM)的临床疗效及患者免疫功能变化.方法分单纯化疗组和化疗+rIL-2组.化疗+rIL-2组于常规化疗(MP或VAD方案为主的方案)同时联合应用rIL-2,用法为100万U,皮下注射,5次/周,连用4周为1个周期,连续应用4个周期后检测免疫指标(T细胞亚群、NK细胞、CD_3~+;CD_(69)~+细胞百分率)变化.采用Blad é标准评价疗效.按照NCI CTCAE(第3版)判断不良反应.结果化疗+rIL-2组治疗后CD_3、CD_4和CD_(56)(NK)阳性百分率及CD_4/CD_8比值均明显高于化疗前和单纯化疔组化疗后水平,总有效率(CR+nCR+PR)、缓解率(CR+nCR)分别为66.7%和25.0%,而单纯化疗组为50.0%和8.3%.rIL-2小良反应轻微.结论 rIL-2能够改善MM化疗患者的免疫功能,提高有效率,降低感染率,值得继续应用.
목적 연구중조인백세포개소-2(rIL-2)연합화료치료다발성골수류(MM)적림상료효급환자면역공능변화.방법 분단순화료조화화료+rIL-2조.화료+rIL-2조우상규화료(MP혹VAD방안위주적방안)동시연합응용rIL-2,용법위100만U,피하주사,5차/주,련용4주위1개주기,련속응용4개주기후검측면역지표(T세포아군、NK세포、CD_3~+;CD_(69)~+세포백분솔)변화.채용Blad é표준평개료효.안조NCI CTCAE(제3판)판단불량반응.결과 화료+rIL-2조치료후CD_3、CD_4화CD_(56)(NK)양성백분솔급CD_4/CD_8비치균명현고우화료전화단순화정조화료후수평,총유효솔(CR+nCR+PR)、완해솔(CR+nCR)분별위66.7%화25.0%,이단순화료조위50.0%화8.3%.rIL-2소량반응경미.결론 rIL-2능구개선MM화료환자적면역공능,제고유효솔,강저감염솔,치득계속응용.
Objective To study the effect of recombinant interlukin-2 plus chemotherapy in treatment of multiple myeloma. Methods We divided into two groups: chemotherapy plus rIL-2 group and simple chemotherapy group. The patients were given at dose of rIL-2 1×l06 IU/d, iH, qd, for 4 weeks and 4cycles. After 4 cycles the changes of T-cell subsets of their peripheral blood were determined. Response was evaluated according to Blad criteria. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria,version 3.0. Results The positive percentages of CD_3, CD_4 NK, CD_(69) and CD_4/CD_8ratio after chemotherapy in chemotherapy plus rIL-2 group were significantly higher than those before chemotherapy in the same group and those after chemotherapy in the other group. The overall response rate and complete response rate were 66.7 % and 25.0 % vs 50.0 % and 8.3 % respectively. The side effects of rIL-2 were predictable and manageable. Conclusion Recombinant interlukin-2 plus chemotherapy could increase immune function of patients with multiple myeloma and has a higher response rate as compared with simple chemotherapy.